Janus Capital Management LLC boosted its position in Sanofi (NYSE:SNY) by 9.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 480,752 shares of the company’s stock after buying an additional 39,606 shares during the period. Janus Capital Management LLC’s holdings in Sanofi were worth $21,754,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in SNY. Dodge & Cox purchased a new stake in shares of Sanofi during the fourth quarter valued at $2,770,485,000. Wells Fargo & Company MN boosted its stake in shares of Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares in the last quarter. Global Financial Private Capital LLC bought a new stake in shares of Sanofi during the first quarter valued at about $35,034,000. Karp Capital Management Corp acquired a new position in shares of Sanofi during the first quarter valued at $26,174,000. Finally, Bank of America Corp DE boosted its position in shares of Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares in the last quarter. 9.97% of the stock is owned by institutional investors.

Shares of Sanofi (NYSE:SNY) traded up 0.42% on Thursday, reaching $47.68. 630,802 shares of the company’s stock were exchanged. Sanofi has a one year low of $36.81 and a one year high of $50.24. The firm has a 50 day moving average of $48.11 and a 200 day moving average of $45.82. The firm has a market capitalization of $120.23 billion, a P/E ratio of 11.34 and a beta of 0.88.

Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the consensus estimate of $0.74. The company had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a return on equity of 37.93% and a net margin of 25.89%. Sanofi’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, equities research analysts predict that Sanofi will post $3.20 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/03/sanofi-nysesny-stake-boosted-by-janus-capital-management-llc-updated-updated-updated.html.

Several brokerages have recently weighed in on SNY. Argus lifted their price target on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. Cowen and Company restated a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a research report on Tuesday. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Zacks Investment Research downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. Finally, BidaskClub downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.